{"name":"NuPathe Inc.","slug":"nupathe-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":-121136000,"cash":30607000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"NP101","genericName":"NP101","slug":"np101","indication":"Acute migraine with or without aura","status":"phase_3"},{"name":"NP101 - Sumatriptan iontophoretic transdermal patch","genericName":"NP101 - Sumatriptan iontophoretic transdermal patch","slug":"np101-sumatriptan-iontophoretic-transdermal-patch","indication":"Acute migraine with or without aura","status":"phase_3"}]}],"pipeline":[{"name":"NP101","genericName":"NP101","slug":"np101","phase":"phase_3","mechanism":"NP101 is a selective serotonin 5-HT1F receptor agonist that reduces migraine pain by constricting cranial blood vessels and inhibiting neuropeptide release.","indications":["Acute migraine with or without aura"],"catalyst":""},{"name":"NP101 - Sumatriptan iontophoretic transdermal patch","genericName":"NP101 - Sumatriptan iontophoretic transdermal patch","slug":"np101-sumatriptan-iontophoretic-transdermal-patch","phase":"phase_3","mechanism":"NP101 delivers sumatriptan through the skin via iontophoresis, a technique using electrical current to enhance transdermal penetration, allowing rapid absorption without needles or oral administration.","indications":["Acute migraine with or without aura"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPdnBiLXlYTVhJdHdfd3VFNHpDNkZLSENJbnNsZmRCTDkyaGJoRGoxNVNoNXZWSFkwNTdFZWtkOENBYnRuZ2NUTFlvR2xLb0pWMDBPaHNkSUtSLVlyc25DVFcyY0o5cTRrc045SEREUDZ6aVNsb244aG5kOHNaS2dsREhwdkFsdkRMV3JURTQtaTM3bnJuTlJhb1pR?oc=5","date":"2024-01-08","type":"pipeline","source":"Drug Target Review","summary":"The science of ageing and restoring healthspan - Drug Target Review","headline":"The science of ageing and restoring healthspan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxQVk93SEVjaXpUMFdSMWZCamxHTnc2eTMtSW0zanQxTzFNZTZtSVZRSDh1clNEY1lfRS05c0loSXZodkl6WUJLcUNHYmV4dFVOaFpYOHZXOFBPZnFfSzFfUEpyOGNhbmRRQi13LWFIdy15MTB5WDdtOVFSUjdHc2RBVXRjd0hBQ1dvVE1NV0JSSmVOS0VDc1FtYVh0WXZxQ193aVJrOVZGQ2lxaWstVWtwckZ6UW9HdVJLVWxBc3dLSEtpR0Y2Ynh3aGEzM3RNNm8wMlo2YWt1ckhoaExy?oc=5","date":"2021-03-22","type":"deal","source":"ACCESS Newswire","summary":"Aytu BioScience Announces Close of Merger with Neos Therapeutics - ACCESS Newswire","headline":"Aytu BioScience Announces Close of Merger with Neos Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOWlBtMmlsUUR3MzFhdWlhaVFyM2t1a1VDcE5QbWpNNHZaRkV1Zzd1RVRvM180TVpGemJWejlFTnVMZDVNZm9GWUZXOGhQNk1GZVg3b2dvUVZscDhsa09vanNGT0ZpNDg4aURLMC1pLVMzWUFINUg3WHFhTXB5ZDlodUlGSG82S1JaVjJsT3NSbUk0YTdOYjVwM0JYWGZ1bnc4LWc5YS14U04?oc=5","date":"2018-12-28","type":"pipeline","source":"Bioprocess Online","summary":"mAbs For Migraines: Crowded Field A Headache For Drug Developers - Bioprocess Online","headline":"mAbs For Migraines: Crowded Field A Headache For Drug Developers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNaUdYTXhseHJ1Z3h5dW1fckVEOElVUUFCdEF6ZHJCMmhoNTY5XzVvTFhnNmM1eE9fcFlBR1ozYkxfcGo3RTR1Mk9ra20zUzFTQTlpQ3o4bHRIWlFONUhzZnJKdGlCZ290LTI0ajVkYWVTLUxJNlp1R2poT0d3QTRhQ2xUNE9PVHRJZk5lRGVvT3p5cGfSAZgBQVVfeXFMTVNtdUJEVndFZUpwcGpvV3RpSXdsY3pUdUZLMTlwUVNic3pKbV90cUExQTdJUmZFaXY4TVBpa20tZG1QUXFFbnBRNWRnWHlQaWhDeTU3N3NxNkQyeU5EVk5OSzJVdlIxYV9zTEp5cHpxOThtODhjTnZ5UXA0QVFvWWlGSHhQN3d2YkRfSEdxSWg0czhFcFFsWkg?oc=5","date":"2016-06-14","type":"pipeline","source":"The Times of Israel","summary":"Teva stops selling migraine patches after reports of burns - The Times of Israel","headline":"Teva stops selling migraine patches after reports of burns","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPbWROR0gtVDAxVTFXNmdYWWJXYVFWa3dKek5PRzVlR1Y3YUNfaXJnRW9saXhNalVVQlNZQVN0M0dHaXpRZEp2dm1oY281ZGFxbWl1LWZaOGcwU2tqRzFmOFc3dURtMk9RZEJTTWNKQWhMcGFjY0g4TUFwY1ktc010M2p3QUsxc3VpejBDYTBweTRtNE5SSVZmb1Y1UDhBOUtEUXhlcC1obk44ZlpsSEQtVlhDWQ?oc=5","date":"2016-06-13","type":"pipeline","source":"The Columbus Dispatch","summary":"Teva stops selling migraine patch after reports of burns - The Columbus Dispatch","headline":"Teva stops selling migraine patch after reports of burns","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTE1qTVlzWWJUNHgxbkFTUVZuSTRWTm8yaWlsenFlVjYzVDNTcHljSGN3ZjN4M3VjcWZRQThTVFhBeXZTQXVBVG9RMmpXN1Rzd3IybFdnNXdvSDBMYVJoaEFGRzRRX3BhdDlXcFcxeVczMzRjV2VyM1E?oc=5","date":"2011-11-11","type":"pipeline","source":"Pharma Voice","summary":"C-Suite: Executive Insights - Pharma Voice","headline":"C-Suite: Executive Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE9sS3ZKYUI5UGdRLWc4YmxBMjFzTjE2SnE3ZERNTFlqaFYxRE12WTVMZ05LMDFNQU5ZYzR4eXV1bmZqUUNxdGcwNUhja2xCMFd3SEhBRlZXcDVSY0JwQ254M1pWVzBUR1ZBLXZpWA?oc=5","date":"2011-07-26","type":"pipeline","source":"Pharma Voice","summary":"Talent Pool - Pharma Voice","headline":"Talent Pool","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQdUs2dkVEVUNGVmhTR2xFd2RlQkZHZnBXU18xUGlvb1BhRi1DTzNQUVFIbTdKSzZrdmJwYTlRTkpFS2lFb1RnRFRlUnYtQklWR0JTTDJHTk80blhLSzhjV25Dc3RpS3lKTDJ3YlBDLW54VXEzN3ZRcXJ3VWhXUk8xSWszbndpVXVaVk5rSVE0czRNb2s?oc=5","date":"2010-10-14","type":"pipeline","source":"Keystone Edge","summary":"Going Against the Migraine: The Rapid Rise of NuPathe - Keystone Edge","headline":"Going Against the Migraine: The Rapid Rise of NuPathe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPU3FGV25tMWs3WlVaRnhYUjBfT2hRZ3JGS0JuaHNOSTN3d1ZWYkVCRFIzeXBDazJjS2Mwbmczd2tjZ3JZVnhSZXBwZFh6OFFqa0NXVl9GRWhTM2stWjRFUXk1NlBIbVY2OGp5QjhKMnd5WVJKTEhpUkxaRjN4OG9oUGJ6YUd2Wjd5RXdZdkNyRzFRQU1H?oc=5","date":"2007-12-10","type":"pipeline","source":"Inquirer.com","summary":"Engaged in serial business-building - Inquirer.com","headline":"Engaged in serial business-building","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-121136000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":30607000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}